Letter | Published:

Lack of interferon response in animals to naked siRNAs

Nature Biotechnology volume 22, pages 15791582 (2004) | Download Citation

Subjects

Abstract

RNA interference (RNAi) is rapidly becoming the method of choice for the elucidation of gene function and the identification of drug targets. As with other oligonucleotide-based strategies, RNAi is envisioned to ultimately be useful as a human therapeutic. Unlike previous nucleic acid therapeutics, small interfering RNAs have the potential to elicit immune responses via interactions with Toll-like receptor 3 and trigger interferon responses like long, double-stranded RNA and its analogs, such as poly(I:C)1. Recently, the safety of siRNAs has been questioned because they have been shown to trigger an interferon response in cultured cells2,3,4,5. We show here that it is possible to administer naked, synthetic siRNAs to mice and downregulate an endogenous or exogenous target without inducing an interferon response.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , & Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732–738 (2001).

  2. 2.

    , , , & Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 771–772 (2003).

  3. 3.

    , , , & Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34, 263–264 (2003).

  4. 4.

    & Small-interfering RNAs in the radar of the interferon system. Nat. Cell Biol. 5, 834–839 (2003).

  5. 5.

    et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 22, 321–325 (2004).

  6. 6.

    et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498 (2001).

  7. 7.

    et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347–351 (2003).

  8. 8.

    et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635–637 (2003).

  9. 9.

    Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135–145 (2001).

  10. 10.

    , & Toll-like receptors as potential therapeutic targets for multiple diseases. Nat. Rev. Drug Discov. 1, 797–807 (2002).

  11. 11.

    et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 101, 5598–5603 (2004).

  12. 12.

    et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529–1531 (2004).

  13. 13.

    et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526–1529 (2004).

  14. 14.

    , , , & Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem. Biophys. Res. Commun. 293, 1364–1369 (2002).

  15. 15.

    et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740–745 (2000).

  16. 16.

    , , , & Effect of different chemically modified oligodeoxynucleotides on immune stimuation. Biochem. Pharmacol. 51, 173–182 (1996).

  17. 17.

    , , , & Toll-like receptor-9 induced by physical trauma mediates release of cytokines following exposure to CpG motif in mouse skin. Immunology 110, 341–347 (2003).

  18. 18.

    , , , & Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. 274, 10689–10692 (1999).

  19. 19.

    et al. Uptake by mouse liver and intracellular fate of plasmid DNA after a rapid tail vein injection of a small or a large volume. J. Gene Med. 5, 142–156 (2003).

  20. 20.

    et al. Hydrodynamics-based transfection of the liver: entrance into hepatocytes of DNA that causes expression takes place very early after injection. J. Gene Med. 6, 877–883 (2004).

  21. 21.

    et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol. 171, 3154–3162 (2003).

  22. 22.

    et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32, 1958–1968 (2002).

  23. 23.

    et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 766–771 (2004).

  24. 24.

    , , & Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol. Ther. 4, 297–306 (2001).

  25. 25.

    et al. Caspase 8 small interfering RNA prevent acute liver failure in mice. Proc. Natl. Acad. Sci. USA 100, 7797–7802 (2003).

  26. 26.

    , , & PKR protection against intranasal vesicular stomatitis virus infection is mouse strain dependent. Viral Immunol. 15, 41–51 (2002).

  27. 27.

    et al. Syntergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 64, 5850–5859 (2004).

  28. 28.

    , , & Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through Toll-Like Receptor 3. J. Immunol. 172, 6545–6549 (2004).

  29. 29.

    & Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312, 1220–1225 (2003).

  30. 30.

    et al. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol. Ther. 10, 269–278 (2004).

Download references

Acknowledgements

The authors would like to thank Jean Lee and Hu Wong for critical blood chemistry and liver panel analyses. We thank Anton McCaffrey and Mark Kay for a donation of the plasmid used in our studies. J.D.H. acknowledges the Whitaker Foundation for a doctoral fellowship. S.H. is supported by an endowment in Molecular Pathology from the Las Madrinas Foundation at CHLA.

Author information

Affiliations

  1. Chemical Engineering, California Institute of Technology, 1200 E. California Boulevard, Pasadena, California 91125, USA.

    • Jeremy D Heidel
    •  & Mark E Davis
  2. Department of Pathology, Children's Hospital Los Angeles, 4650 Sunset Boulevard, California 90027, USA.

    • Siwen Hu
    • , Xian Fang Liu
    •  & Timothy J Triche

Authors

  1. Search for Jeremy D Heidel in:

  2. Search for Siwen Hu in:

  3. Search for Xian Fang Liu in:

  4. Search for Timothy J Triche in:

  5. Search for Mark E Davis in:

Competing interests

M.E.D. is a consultant to and has a financial interest in Insert Therapeutics, Inc.

Corresponding author

Correspondence to Mark E Davis.

Supplementary information

PDF files

  1. 1.

    Supplementary Fig. 1

    RNase digestion of poly(I:C) and siRNA.

  2. 2.

    Supplementary Fig. 2

    Synthetic siRNA does not alter mouse CBC or liver enzyme levels.

  3. 3.

    Supplementary Fig. 3

    Degradation kinetics of synthetic siRNA in mouse serum.

  4. 4.

    Supplementary Fig. 4

    Sequence-specific target down-regulation by siRNA in RAW-264.7 cells.

  5. 5.

    Supplementary Fig. 5

    Synthetic siRNA accomplishes sequence-specific RNAi of an exogenous target in mice.

  6. 6.

    Supplementary Fig. 6

    Lack of IL-12 and IFN-a induction by siRNA in C57BL/6 mice.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt1038

Further reading